−3.23USD
−6.98 MUSD
75.72 KUSD
3.24 M
About Arch Therapeutics, Inc.
Sector
Industry
CEO
Terrence W. Norchi
Website
Headquarters
Framingham
Employees (FY)
8
Founded
2009
ISIN
US03939W2089
FIGI
BBG002PHNCD4
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ARTH is 1.20 USD — it has increased by 1.27% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Arch Therapeutics, Inc. stocks are traded under the ticker ARTH.
Arch Therapeutics, Inc. is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
ARTH stock is 1.26% volatile and has beta coefficient of 6.81. Check out the list of the most volatile stocks — is Arch Therapeutics, Inc. there?
ARTH earnings for the last quarter are −0.32 USD per share, whereas the estimation was 2.00 USD resulting in a −116.00% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about Arch Therapeutics, Inc. earnings.
Arch Therapeutics, Inc. revenue for the last quarter amounts to 1.20 M USD despite the estimated figure of 3.84 M USD. In the next quarter revenue is expected to reach 1.40 M USD.
Yes, you can track Arch Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ARTH stock has fallen by 19.80% compared to the previous week, the month change is a 36.10% fall, over the last year Arch Therapeutics, Inc. has showed a 62.18% decrease.
ARTH net income for the last quarter is −2.68 M USD, while the quarter before that showed −2.46 M USD of net income which accounts for −9.13% change. Track more Arch Therapeutics, Inc. financial stats to get the full picture.
Today Arch Therapeutics, Inc. has the market capitalization of 5.60 M, it has decreased by 10.27% over the last week.
No, ARTH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ARTH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arch Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 8.00 employees. See our rating of the largest employees — is Arch Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arch Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arch Therapeutics, Inc. stock shows the strong sell signal. See more of Arch Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arch Therapeutics, Inc. EBITDA is −5.26 M USD, and current EBITDA margin is −6.66 K%. See more stats in Arch Therapeutics, Inc. financial statements.